# ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

> **NCT06838676** · PHASE2 · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Diffuse Intrinsic Pontine Gliomas (DIPG)
- Progressive DIPG
- Refractory DIPG
- Recurrent DIPG
- H3K27-altered High Grade Glioma

## Interventions

- **DRUG:** ACT001

## Key facts

- **NCT ID:** NCT06838676
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-10
- **Primary completion:** 2028-07
- **Final completion:** 2035-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06838676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06838676, "ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06838676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*